Table 1 Clinicopathological characteristics of patients with HCC between groups with different RPL27A expression levels
From: High expression of RPL27A predicts poor prognosis in patients with hepatocellular carcinoma
|  | Overall (n = 76) | Low-level (n = 34) | High-level (n = 42) | P value |
|---|---|---|---|---|
Age of diagnosis | ||||
  ≤ 50 years | 32 (42.1%) | 16 (47.1%) | 16 (38.1%) | 0.580 |
  > 50 years | 44 (57.9%) | 18 (52.9%) | 26 (61.9%) | |
Gender | ||||
 Male | 70 (92.1%) | 30 (88.2%) | 40 (95.2%) | 0.485 |
 Female | 6 (7.9%) | 4 (11.8%) | 2 (4.8%) | |
HBsAg | ||||
 Negative | 15 (19.7%) | 7 (20.6%) | 8 (19.0%) | 1.000 |
 Positive | 61 (80.3%) | 27 (79.4%) | 34 (81.0%) | |
AFP | ||||
 Negative | 32 (42.1%) | 18 (52.9%) | 14 (33.3%) | 0.137 |
 Positive | 44 (57.9%) | 16 (47.1%) | 28 (66.7%) | |
Tumor size | ||||
  ≤ 50 mm | 53 (69.7%) | 23 (67.6%) | 30 (71.4%) | 0.916 |
  > 50 mm | 23 (30.3%) | 11 (32.4%) | 12 (28.6%) | |
Cirrhosis | ||||
 Negative | 9 (11.8%) | 6 (17.6%) | 3 (7.1%) | 0.293 |
 Positive | 67 (88.2%) | 28 (82.4%) | 39 (92.9%) | |
Grade | ||||
 Grades I and III | 34 (44.7%) | 18 (52.9%) | 16 (38.1%) | 0.288 |
 Grade II | 42 (55.3%) | 16 (47.1%) | 26 (61.9%) | |
Stage | ||||
 I | 50 (65.8%) | 23 (67.6%) | 27 (64.3%) | 0.949 |
 II and III | 26 (34.2%) | 11 (32.4%) | 15 (35.7%) | |
PD-1 | ||||
 Negative | 38 (50.0%) | 18 (52.9%) | 20 (47.6%) | 0.818 |
 Positive | 38 (50.0%) | 16 (47.1%) | 22 (52.4%) | |